Search results for "Time-to-Treatment"

showing 10 items of 31 documents

Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey

2018

Abstract Background The Icatibant Outcome Survey (IOS; NCT01034969) is a Shire‐sponsored, international, observational study monitoring the safety and effectiveness of icatibant, a bradykinin B2 receptor antagonist approved for the acute treatment of adults with hereditary angioedema with C1 inhibitor deficiency (HAE‐C1‐INH). Objective To report IOS data comparing demographic and icatibant treatment outcomes in patients with HAE‐C1‐INH from Germany to HAE‐C1‐INH patients from 11 other IOS countries. Methods A descriptive, retrospective, comparative analysis of data from 685 IOS patients with HAE‐C1‐INH from seven centres in Germany (n = 93) vs. centres from Austria, Brazil, Czech Republic, …

0301 basic medicineAdultMalePediatricsmedicine.medical_specialtyTime FactorsC1 inhibitor deficiencyTime to treatmentDermatologyBradykininAutoimmune DiseasesTime-to-Treatment03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIcatibantGermanyBradykinin B2 Receptor AntagonistsmedicineHumansIn patientSymptom onsetRetrospective Studiesbusiness.industryAngioedemas HereditaryMiddle Agedmedicine.diseaseSymptom Flare UpHealth Surveys030104 developmental biologyInfectious Diseases030228 respiratory systemchemistryHereditary angioedemaObservational studyOriginal ArticleFemaleOutcome databusinessJournal of the European Academy of Dermatology and Venereology
researchProduct

Patients With Cancer and COVID-19: A WhatsApp Messenger-Based Survey of Patients' Queries, Needs, Fears, and Actions Taken

2020

PURPOSE This descriptive investigation was undertaken at three oncology units to report queries, needs, and fears related to severe acute respiratory syndrome coronavirus 2 (COVID-19) of patients with cancer and to avoid uncontrolled treatment delays or withdrawal, behavioral mistakes, and panic. PATIENTS AND METHODS All queries spontaneously delivered through the WhatsApp instant messaging system commonly used by patients to communicate with oncology units were collected and grouped by homology in five categories. Responses to the queries were given according to recommendations by the Italian Association of Medical Oncology through WhatsApp and by subsequent phone calls. Patients were also…

0301 basic medicineCancer Research2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)WhatsApp messenger cancer patient reactions action taken COVID-19 outbreak sentimental analysisPneumonia ViralMEDLINETime to treatmentTime-to-Treatment03 medical and health sciences0302 clinical medicineNeoplasmsSurveys and QuestionnairesOriginal ReportsPandemicmedicineHumansIntensive care medicinePandemicsText Messagingbusiness.industryCOVID-19CancerFearmedicine.diseasePneumonia030104 developmental biologyOncology030220 oncology & carcinogenesisCoronavirus Infectionsbusiness
researchProduct

Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia

2016

This test decreased time to treatment initiation by 66%–84%.

0301 basic medicineOncologyMaleEpidemiologylcsh:Medicine0302 clinical medicine1108 Medical MicrobiologyTuberculosis Multidrug-Resistant030212 general & internal medicinebacteriaDecreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test Latviabiologytime to treatment initiationDrug Resistance MicrobialMiddle Agedmultidrug-resistant tuberculosisRifampin resistanceInfectious Diseases1117 Public Health And Health ServicesTuberculosis Multidrug-Resistant/diagnosisFemaleRifampinLife Sciences & BiomedicineMicrobiology (medical)Adultmedicine.medical_specialtyTuberculosisAdolescentpulmonary030106 microbiologyXpert MTB/RIFImmunologyTime to treatmentMicrobiologylcsh:Infectious and parasitic diseasesTime-to-TreatmentMycobacterium tuberculosismolecular diagnostics03 medical and health sciencesYoung AdultAntibiotic resistancemultidrug resistanceInternal medicinemedicineHumanslcsh:RC109-216Multivariable modelantimicrobial resistanceTuberculin testAntibiotics AntitubercularScience & Technologybusiness.industryTuberculin TestResearchlcsh:RMycobacterium tuberculosis/drug effects1103 Clinical SciencesMycobacterium tuberculosisbiology.organism_classificationmedicine.diseaseAntibiotics Antitubercular/pharmacologyLatviatuberculosis and other mycobacteriaMultiple drug resistanceMODELTuberculin Test/methodsbusinessRifampin/pharmacologyMDR TB
researchProduct

Impact of COVID-19 on global HCV elimination efforts.

2021

Background & Aims COVID-19 has placed significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination. Mathematical models can be used to evaluate the possible impact of programmatic delays on hepatitis disease burden. The objective of this analysis was to evaluate the incremental change in hepatitis C liver-related deaths and liver cancer, following a 3-month, 6-month, or 1-year hiatus in hepatitis elimination program progress. Methods Previously developed models were adapted for 110 countries to include a status quo or “no delay” scenario and a “1-year delay” scenario assuming significant disruption in interventions (screening, diagnosis and …

0301 basic medicinePsychological interventioncoronavirusUMIC upper-middle income countriesGlobal HealthUI uncertainty intervalHIC high income countries0302 clinical medicineCost of IllnessLIC low income countriesMedicineUSA United States of AmericaLetter to the EditorMathematical modellingPWID people who inject drugsLiver DiseaseLiver DiseasesVaccinationmathematical modelingGBD Global Burden of DiseaseHepatitis CSVR sustained virologic responseEuropeHCV hepatitis C virusHepatocellular carcinomaHCVGHSS Global Health Sector StrategyRNA Viral030211 gastroenterology & hepatologyAMR region of the AmericasLiver cancerViral hepatitisHumanCarcinoma HepatocellularCoronavirus disease 2019 (COVID-19)EMR Eastern Mediterranean regionViral hepatitis eliminationviral hepatitisContext (language use)World Health OrganizationArticleWHO World Health OrganizationTime-to-Treatment03 medical and health scienceseliminationEnvironmental healthHumansLMIC lower-middle income countriesDisease EradicationDisease burdenHepatitisHepatologySARS-CoV-2business.industryWPR Western Pacific regionCOVID-19Models Theoreticalmedicine.diseaseCost of Illne030104 developmental biologySpainHCC hepatocellular carcinomabusinessJournal of hepatology
researchProduct

Will the COVID-19 pandemic affect HCV disease burden?

2020

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Pneumonia ViralTime to treatmentAffect (psychology)Antiviral AgentsArticleTime-to-TreatmentBetacoronavirusPandemicHumansMedicineDisease EradicationPandemicsDisease burdenAntiviral AgentDisease EradicationbiologyHepatologyBetacoronaviruPandemicbusiness.industryCoronavirus InfectionSARS-CoV-2GastroenterologyCOVID-19Hepatitis C Chronicbiology.organism_classificationVirologyCoronavirus InfectionsbusinessBetacoronavirusHuman
researchProduct

The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four European countries

2021

Eliminació del VHC; Punt d'equilibri; Infecció d'hepatitis C Eliminación del VHC; Punto de equilibrio; Infección de hepatitis C HCV elimination; Break-even; Hepatitis C infection Background and Aims We assessed the clinical and economic impact of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) in England, Italy, Romania and Spain. Methods An HCV progression Markov model was developed considering DAA eligibility and population data during the years 2015-2019. The period of time to recover the investment in DAAs was calculated as the cost saved by avoiding estimated clinical events for 1000 standardized treated patients. A delayed treatment scenario because of coronavirus di…

:Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost Control::Cost Savings [HEALTH CARE]DiseaseHepacivirusmedicine.disease_cause:Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis Viral Human::Hepatitis C [DISEASES]0302 clinical medicineCost of IllnessMedicine:Other subheadings::/therapeutic use [Other subheadings]Economic impact analysisChronicExit strategyevenLiver NeoplasmsHealth services researchhealthInvestment (macroeconomics)Hepatitis C:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS]break‐EnglandItalyHCV elimination030220 oncology & carcinogenesisOriginal Article030211 gastroenterology & hepatologyLiver Disease and Public HealthHumanHepatitis C virusSettore SECS-P/03hepatitis C infectionMedicaments antivírics- Ús terapèuticAntiviral AgentsTime-to-Treatment03 medical and health sciencesbreak-evenHumansbusinessDisease burdenDAAAntiviral Agent:economía y organizaciones para la atención de la salud::economía::costes y análisis de costes::control de costes::ahorro de costes [ATENCIÓN DE SALUD]HepaciviruHepatology:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryRomania:enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis viral humana::hepatitis C [ENFERMEDADES]COVID-19break‐evenDAAsHepatitis C ChronicEstalvi i inversióHcv eliminationCost of IllneSpain:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS]Communicable Disease ControlVirus de l'hepatitis CbusinessDemography
researchProduct

Attitudes towards insulin initiation in type 2 diabetes patients among healthcare providers: A survey research

2016

Aims: To describe the views of healthcare providers about starting insulin in patients with type 2 diabetes and to determine the specific factors that contribute to delay insulin initiation. Methods: Two-phases observational descriptive study. In the quantitative phase we conducted a cross-sectional survey of a sample of 380 healthcare professionals (general practitioners (GPs), endocrinologists, internists and nurses). In the qualitative phase, a discussion group reviewed the results of the survey to propose solutions. Results: In poorly controlled patients, 46% of GPs vs. 43.2% of internists and 31.3% of endocrinologists waited 3-6 months before starting insulin, and 71.4% of GPs vs. 66.7…

AdultBlood GlucoseMaleHealth Knowledge Attitudes Practicemedicine.medical_specialtyTime FactorsAttitude of Health PersonnelHealth PersonnelEndocrinology Diabetes and Metabolismmedicine.medical_treatmenteducation030209 endocrinology & metabolismTime-to-treatmentsType 2 diabetes03 medical and health sciencesDiabetes mellitus0302 clinical medicineEndocrinologySurveys and QuestionnairesDiabetes mellitusInternal medicineDisease managementInternal MedicineHumansInsulinMedicine030212 general & internal medicinePractice Patterns Physicians'Disease management (health)Glycemicbusiness.industryInsulinGeneral MedicineMiddle Agedmedicine.diseaseCross-Sectional StudiesEndocrinologyDiabetes Mellitus Type 2Basal (medicine)SpainFamily medicineFemaleObservational studyGeneral practicebusinessHealthcare providersType 2Diabetes Research and Clinical Practice
researchProduct

Rickettsia typhi and Haemophagocytic Syndrome

2017

Appropriate therapy (dexamethasone, cyclosporin, and etoposide) could save the patient in those cases in which the pathogen-direct therapy has not been sufficient by itself to control the disease.

AdultMaleFeverVomiting030231 tropical medicineTime-to-Treatment03 medical and health sciences0302 clinical medicineFatal OutcomeVirologyRickettsia typhiMedicineAnimalsHumansTreatment FailureRickettsia prowazekiiRickettsia typhileishmaniasisLetter to the EditorTransaminasesAgedAged 80 and overbiologybusiness.industryNauseaTyphus Endemic Flea-BorneExanthemaMiddle Agedbiology.organism_classificationVirologyTexasThrombocytopeniaAnti-Bacterial AgentsInfectious Diseases030211 gastroenterology & hepatologyParasitologyFemalebusinessTyphus Epidemic Louse-BorneThe American Journal of Tropical Medicine and Hygiene
researchProduct

The long and complex road in the search for treatment for mental disorders: An analysis of the process in five groups of patients

2016

Seeking treatment for mental-health problems is a complex process, with different underlying motives in each stage. However, the entire process and these motives have hardly been investigated. This study aims to analyze the different stages of the help-seeking process and their underlying motives in five groups of patients with different mental disorders. In all, 156 patients seeking treatment in outpatient mental health clinics were individually interviewed: 71 had Obsessive-Compulsive Disorder (OCD), 21 had Agoraphobia (AGO), 18 had Major Depressive Disorder (MDD), 20 had Anorexia Nervosa (AN), and 22 had Cocaine Dependence (COC). The AGO and MDD patients delayed significantly less time i…

AdultMaleObsessive-Compulsive Disordermedicine.medical_specialtyAnorexia NervosaSocial stigmaSocial StigmaPoison controlSuicide preventionTime-to-TreatmentCocaine dependenceCocaine-Related Disorders03 medical and health sciencesHelp-Seeking Behavior0302 clinical medicinemental disordersInjury preventionmedicineHumansPsychiatryAgoraphobiaBiological PsychiatryDepressive Disorder Majorbusiness.industryMental DisordersMiddle Agedmedicine.diseaseMental health030227 psychiatryPsychiatry and Mental healthMajor depressive disorderFemalebusinessAttitude to Health030217 neurology & neurosurgeryAgoraphobiaClinical psychologyPsychiatry Research
researchProduct

Predictors of clinical remission following a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables

2012

The aim of the study was to identify predictors associated with a lower likelihood of achieving a clinical remission 1 year after the first break of the illness. Participants were 174 consecutive subjects included in a first episode programme with no prior treatment with antipsychotic medication. Patients were assigned to haloperidol, olanzapine or risperidone in a randomized, open-label, prospective clinical trial. The main outcome variable was the remission criteria developed by the Remission in Schizophrenia Working Group. Clinical variables were included in a logistic regression analysis in order to predict the remission state at 1 year. At 1 year, 31% of patients met criteria for remis…

AdultMaleOlanzapinePediatricsmedicine.medical_specialtymedicine.medical_treatmentLogistic regressionSeverity of Illness IndexTime-to-TreatmentBenzodiazepinesYoung AdultRisk FactorsmedicineHumansLongitudinal StudiesAntipsychoticPsychiatryBiological PsychiatryFirst episodeRisperidoneRemission InductionPrognosisRisperidonemedicine.diseaseClinical trialPsychiatry and Mental healthLogistic ModelsPsychotic DisordersOlanzapineSchizophreniadupSchizophreniaEducational StatusHaloperidolFemaleSchizophrenic PsychologyPsychologyAntipsychotic Agentsmedicine.drugPsychiatry Research
researchProduct